Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and ...

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and short-term investments of $56.2M vs. $76.6M as of ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through ...